Skip to main content
    T

    Transcode Therapeutics Inc (RNAZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    +0.05 (+3.70%)

    Market Cap: $22.35M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Transcode Therapeutics Inc (RNAZ) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Transcode Therapeutics (RNAZ) has a latest price of $1.40 on Nov 17, 2026, 88.9% below its 52-week high of $12.60. Its price fell 84.8% over the past 12 months. The month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 94.0%.

    Price Chart

    From Jul 2021 to Oct 2026, its highest month-end close was $2,248,292.06 in Aug 2021 and its lowest $1.63 in Oct 2026, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart RNAZ with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RNAZ.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 56.4%, and over 6 months it fell 77.3%. The month-end price fell 100.0% over the 3 years through Oct 2026, a compound annual decline of 95.1%.

    PeriodChange
    1 month-17.6%
    3 months-56.4%
    6 months-77.3%
    12 months-84.8%
    12 months, with dividends-84.8%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years-100.0%-95.1%
    5 years-100.0%-94.0%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2022, when the price fell 73.5%, and its weakest was 2023, when it fell 98.8%.

    YearCloseChange
    2026 through Oct 2026$1.63-76.1%
    2025$6.83-92.8%
    2024$94.40-98.5%
    2023$6,094.05-98.8%
    2022$497,730.45-73.5%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 14.7% below its 50-day average of $1.64 and 75.2% below its 200-day average of $5.64.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$1.40
    52-week high$12.60-88.9%
    52-week low$1.29+8.5%
    50-day average$1.64-14.7%
    200-day average$5.64-75.2%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 100.0%.

    MeasureValue
    1-year beta0.76
    Largest fall, 1 year-89.3%
    Largest fall, 3 years-100.0%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About RNAZ

    What is RNAZ's 1-year price change?

    Transcode Therapeutics's price fell 84.8% over the past 12 months. With dividends included, the 12-month total return was -84.8%.

    What is RNAZ's 5-year price change?

    Transcode Therapeutics's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 94.0%. These figures leave out dividends.

    What is RNAZ's 52-week high and low?

    Transcode Therapeutics's 52-week high is $12.60 and its 52-week low is $1.29. Its latest price of $1.40 on Nov 17, 2026 is 88.9% below the high.

    What is RNAZ's beta?

    Transcode Therapeutics's 1-year beta against the S&P 500 is 0.76, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 89.3%.

    Is the RNAZ chart free?

    Yes. Advanced Charting for RNAZ is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.